Latest revenue
$0
as of 2026-03-31
Latest net income
$-43.8K
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.6M
- Enterprise value
- $1.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.10
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 60.0M
5-year trend
What this company does
Acro Biomedical resells cordyceps, a fungus used in traditional Chinese medicine, sourcing it from Taiwanese suppliers and selling in bulk to distributors who incorporate it into their own products. Historically, nearly all revenue came from cordyceps sales made personally by its part-time CEO, with one Taiwanese supplier providing 100% of inventory in 2022. The company is effectively dormant: it has generated no sales since 2022, holds no inventory, lost its sole employee-CEO to resignation in August 2025, and survives on advances from a minority shareholder.
Generated from ACBM's filing dated 2026-02-11
Key risks
- Going concern: no revenue since Q2 2022, nominal cash, no inventory, and no purchases since mid-2022 through filing date.
- Leadership void: sole employee/CEO Pao-Chi Chu resigned August 14, 2025; financing depends on discretionary advances from a minority stockholder.
- Stock illiquidity: trades on OTC Expert Market with no published quotes, making equity raises highly dilutive or impractical.
Generated from ACBM's filing dated 2026-02-11
Profitability
Gross margin
21.3%
1.5%Operating margin
-2410.0%
275.1%Net margin
-2410.2%
274.9%Return on equity
26.1%
82.3%Return on assets
-717.4%
442.3%Leverage
Debt / equity
-1.04×
6.5%Debt / assets
2844.8%
178.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | — | $-43.8K | -324.9% | — |
Q4 2025 2025-12-31 | $0 | — | $42.5K | +498.4% | — |
Q3 2025 2025-09-30 | $0 | — | $-117.8K | -1051.7% | — |
Q2 2025 2025-06-30 | $0 | — | $-15.6K | -53.4% | — |
Q1 2025 2025-03-31 | $0 | — | $-10.3K | +8.5% | — |
Q4 2024 2024-12-31 | $0 | — | $-10.7K | — | — |
Q3 2024 2024-09-30 | $0 | — | $-10.2K | +99.4% | — |
Q2 2024 2024-06-30 | $0 | — | $-10.1K | +99.7% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Amusement & Recreation Services · SIC 7900
Your notes
Keep private notes on ACBM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ACBM in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ACBM
No institutional holdings on file for ACBM yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
- 1
With zero revenue since 2022, no inventory, no employees after Chu's August 2025 resignation, what is management's concrete plan to avoid dissolution?
- 2
Given nominal cash and reliance on minority stockholder advances, what are the outstanding balances, terms, and any repayment demands threatening solvency?
- 3
Why should shareholders not view ACBM as an abandoned shell, and is the board pursuing a reverse merger or liquidation?
Refreshed when ACBM files a new report · last from 2026-02-11